After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

Vaccine maker Novavax stock jumped double digits on Thursday after the company reported its quarterly sales had more than ...

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the ...

Novavax highlighted that they believe their BLA for Nuvaxovid is approvable based on their conversations with the FDA to date and this additional data would be generated after BLA approval ...

Novavax (NASDAQ:NVAX) shares climbed ~35% in the premarket on Thursday after the COVID-19 vaccine maker lifted its full-year ...

Sanofi Supply Sales Novavax will sell Nuvaxovid commercial supply to Sanofi for the 2025-2026 vaccination season and the reimbursement for this supply will be recorded as product sales.

Nuvaxovid sales reached $608 million, up from $82 million a year ago. Cost of sales for the first quarter of 2025 was $14 million, compared to $59 million in the same period in 2024. R&D expenses ...